



The apoA-I companY

Press Release

ABIONYX Pharma announces its financial calendar for the year 2025

Toulouse, FRANCE, Lakeland, UNITED-STATES, January 13th, 2025, 6:00 pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today announces its financial calendar for 2025.

| Events | Dates* |
|---|------------------------------|
| Cash position and activity update for Q4 2024 | Thursday, February 27, 2025 |
| 2024 Full-Year Results | Thursday, March 6, 2025 |
| Cash position and activity update for Q1 2025 | Wednesday, May 28, 2025 |
| Cash position and activity update for Q2 2025 | Thursday, August 28, 2025 |
| 2025 Half-Year Results | Thursday, September 25, 2025 |
| Cash position and activity update for Q3 2025 | Tuesday, November 25, 2025 |

** indicative dates subject to change*

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.

Contacts:

NewCap

Investor relations
Nicolas Fossiez
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15